Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Launched by ROSWELL PARK CANCER INSTITUTE · May 24, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring a new method called pulmonary suffusion, which involves delivering chemotherapy directly to the lungs to help control cancer that has spread to this area. The main goal is to see if this approach can effectively target minimal residual disease in patients with certain types of cancer, including sarcoma and colorectal cancer. By using a treatment like cisplatin, which is a type of chemotherapy, the researchers hope to find a way to slow down or stop the growth of these tumors while reducing the need for additional treatments through the veins.

To be eligible for this trial, participants should have lung tumors from specific cancers such as soft tissue sarcoma or colorectal cancer, and their overall health must meet certain criteria. For example, they should be able to walk a certain distance in six minutes and have good lung function. If someone joins the trial, they will receive the pulmonary suffusion treatment and will be monitored for any side effects. It’s important for potential participants to understand the investigational nature of this study and to agree to follow the study guidelines carefully.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Tumors metastatic to the lungs that are the focus of this protocol specifically:
• • Soft tissue sarcoma
• • Osteosarcoma
• • Colorectal carcinoma
• • Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
• • Hemoglobin \> 8.0 g/L
• • Granulocytes \> 1,500 uL
• • Platelets \>= 100,000 uL
• • Creatinine clearance \>= 30 mL/min
• • Clinically diagnosed resectable sarcoma lung metastases(while preregistration histologic or cytologic confirmation is desirable, this may not be required in clinical scenarios where a biopsy may not change the need to resect suspicious lung nodules or the biopsy itself poses a risk for tumor seeding. In such cases, the diagnosis will be supported by rapid pathologic evaluations intraoperatively before proceeding with Suffusion) Given the emergence of other acceptable options to destroy lung metastases such as SBRT or microwave ablation, a hybrid approach to eliminate all sites of disease will be permitted; however, supplemental approaches should be delayed, if possible, until after the 30 day post-suffusion endpoint
• • Forced expiratory volume in 1 second (FEV1) \>= 50% predicted
• • Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% predicted
• • Vital capacity (VC) \>= 50% predicted
• • Ambulatory and resting oxygen (O2) saturation \> 88%
• • Six minute walk \>= 50 % of the expected distance
• • Surgeon affirmation that suffusion is technically feasible
• • Borg Dyspnea scale (modified) \< 5
• • Control of the primary tumor as determined by clinical assessment per standard of care; may include stable tumor status of primary tumor and other metastases, in the clinical judgement of the PI/Physician.
• • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
• Exclusion Criteria:
• • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
• • Allergy, intolerance, or other serious reaction to chemotherapy drugs that may be used in the procedure
• • Pregnant or nursing female participants
• • Unwilling or unable to follow protocol requirements
• • Pulmonary metastases unable to be completely resected or ablated based on pre-registration review of imaging by a thoracic surgeon or proceduralist.
• • Any additional condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug or the suffusion technique, may include uncontrolled intercurrent illness and other conditions that, in the judgement of the PI/Physician, would limit compliance with the study requirements and have safety concerns
• • Received an investigational agent within 30 days prior to enrollment
• • Severe peripheral neuropathy